


IN THE APPLICATION:

Please delete page 1 of the application as filed containing the Sequence Listing and insert substitute page 1 enclosed herewith, which contains the amended Sequence Listing.

REMARKS

The Communication asserts that the application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. §§ 1.821-1.825. Applicants have amended the applications to include a substitute Sequence Listing which contains the nucleotide and/or amino acid sequences disclosed in the application. New page 1 are provided to comply with the Sequence Rules set forth in 37 C.F.R. §§ 1.821-1.825. Enclosed is a copy of: the Notice to Comply with Requirements For Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, A Response to the Notice to Comply with Requirements For Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, a Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 C.F.R. §§ 1.821-1.825, and a computer readable form (CRF). No new matter has been added.

Respectfully submitted,

 Date: 5/3/05

Donna T. Ward, Ph.D.

Registration No. **48,271**

Isis Pharmaceuticals, Inc

1896 Rutherford Rd.

Carlsbad, CA 92008

(760) 931-9200 – General Phone

(760) 603-3820 – Facsimile